Table 3.

Overview of 11 studies reporting about prosthesis retention at the site of periprosthetic hip joint infections with regard to the systemic antibiotic therapy

Study	Systemic antibiotic therapy
Aboltins et al[6]	All intravenous glycopeptide or beta-lactam for median 10 (3-29) d
	All oral rifampicin+fusidic acid for median 17 (6-33) mo
Aboltins et al[7]	All intravenous glycopeptide + beta-lactam for median 15 (12-34) d
	All oral rifampicin + fucidic acid or ciprofloxacin for median 356 (230-395) d
Anagnostakos et al[8]	All intravenous for 4 wk + oral for 2 wk
Choi et al[9]	All intravenous for 6 wk
Crockarell et al[10]	41/42 intravenous for 29 (2-72) d
	26/42 oral after iv For 70 (5-376) d; 3/42 chronic suppression
Kelm et al[11]	Intravenous for 2 wk followed by oral for 2 wk
Klouche et al[12]	Intravenous for 6 wk followed by oral for 6 wk
Lee et al[13]	Intravenous for 4-6 wk
Tsukayama et al[2]	Early: intravenous for 4 wk; acute hematogenous: intravenous for 6 wk
Waagsbø et al[3]	Overall duration of antibiotic therapy 0.1 (8.2-14.2) wk, of which intravenous 4.4 (4.2-6.1) wk
Westberg et al[14]	Overall duration of antibiotic therapy 7 (3-39) wk